Distributed by:

CliniSciences Group

The antibody drugs have increasingly fewer adverse reactions because of their high specificity. Therefore, therapeutic antibody has become the predominant class of new drugs developed in recent years. The whole research and development process of antibody drugs basically takes 10 years, from the initial identification of targets, to screening of therapeutic antibody candidates for pre-clinical studies, to entering phase Ⅰ / Ⅱ / Ⅲ clinical trails, then completing the final declaration of NDA (new drug application). Throughout the whole process of antibody drug development, therapeutic antibody candidate screening service is the beginning of antibody-based drug discovery, and it is crucial as well.

CUSABIO has been working on the development and production of proteins and antibodies for more than 17 years and successfully screened 100+ therapeutic antibody candidates for pharmaceutical companies already, many of which have entered the CMC or IND phases. For some druggable targets that are difficult to produce, such as CLDN18.2, CLDN6, CCR8, SSTR2, DLL3, LY6G6D, ROR1, SEMA4D, GPC3, CD16A and so on, we not only successfully had produced antigens, but also successfully screened corresponding therapeutic antibody candidates already. CUSABIO has 3 platforms for production of transmembrane proteins. Mostly, we have completed 30+ projects of screening services for therapeutic antibody candidates targeting multiple transmembrane proteins. So we can confidently promise that CUSABIO has rich experiences in therapeutic antibody discovery targeting multipass transmembrane protein, mostly, we can offer the therapeutic antibody discovery service to you as risk-free, we can promise that we will not charge anything if we failed in screening.

CUSABIO can provide a one-stop solution from target to therapeutic antibody candidate to accelerate the entire development process for you.



Distributed by:

CliniSciences Group

Service Process


Reference antibody preparation


Antigen production


Stable cell line construction

Risk-free for Antigen Production
No protein, No charge


Mice immunization



Cell fusion

Multiple Immunization Solutions
- **GMP animal facility**
- **Multiple types of Mice**
- **Multiple adjuvants**


Screening and selection


Hybridoma cell culture

Screening through Antigen-specific ELISA and Cell-based FACS Assays
- **The positive rate of ELISA screening could be 20%-40%**
- **The positive rate of FACS screening could be 10%-20%**


Sub-cloning and cell culture


Screening and selection


Recombinant antibody production


Hybridoma cell sequencing

Hybridoma cell sequencing: Top 50 or even more could be delivered


QC of recombinant antibody


Recombinant antibody delivery